• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 4, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

GlycoNet awards grants worth $90,000 to three Alberta startup companies

Bioengineer by Bioengineer
October 9, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

EDMONTON (October 9, 2018) – The Canadian Glycomics Network (GlycoNet) awarded $90,000 in grants to three Alberta-based startup companies: 48Hour Discovery Inc., GlyCa BioSciences Inc. and PanTHERA CryoSolutions Inc.

The Startup Company Funding Program recognizes the needs of start-up companies and provides financial help to increase their chances of success. The financial support can be used for the recruitment of business development staff, for leveraging funding from other sources, and for patent protection and licensing activities. All three awarded companies were created based on technologies developed through GlycoNet-funded research.

"It's important for GlycoNet to help the creation of glyco-based startup companies and increase their chances of success" says Dr. Elizabeth Nanak, Executive Director, GlycoNet. "This funding program is an integral part of our commercialization strategy. Ideally, we want to see innovative technologies translated into tangible outcomes within the next 5-10 years."

48Hour Discovery Inc.
Total grant: $20,000

48Hour Discovery Inc. (48HD) accelerates the drug discovery process by providing ligand screening services within just 48 hours. The company received $20,000 for patent filing payments.

"Commercialization grant opportunities, such as the ones available at GlycoNet, are essential for the sustainable growth of early entrepreneurial enterprises," says Dr. Ratmir Derda, President, 48HD. "As a technology company, our intellectual property is at the core of what we do. The $20,000 we received from GlycoNet for patent filing costs helps us manage the necessary expenses when navigating the patenting process."

GlyCa BioSciences Inc.
Total grant: $20,000

GlyCa BioSciences has a technology that uses an sugar as a cancer biomarker, which together with tissue-specific markers, can detect and/or predict high-risk prostate cancer with a simple blood test. GlyCa BioSciences received $20,000 for patent filing costs.

"GlyCa BioSciences recently received $20,000 for patent filing costs which will significantly help the company as it moves forward with the development of an extracellular vesicle-based 'liquid biopsy' for detection of aggressive prostate cancer," says co-founder Dr. Karla Williams, University of British Columbia. "The successful filing of Glyca's patent application, made possible through GlycoNet StartUp Company Funding Program, will enable the development of a protected marketing strategy and enhance the company's commercial success. Patent protection for Glyca Biosciences 'liquid biopsy' is intrinsically linked with the company's goal of continued product development and further innovations to strengthen the product and drive its commercialization."

PanTHERA CryoSolutions Inc.
Total grant: $50,000

PanTHERA CryoSolutions' technology provides a much needed improvement in the cryopreservation of cells and tissues, resulting in better quality cells for cellular therapies and transplantations. The company was awarded $50,000 for the recruitment of a commercialization associate to help the company business development activities.

"The New Company StartUp Funding Program with GlycoNet has been essential for the creation of PanTHERA CryoSolutions, a newly formed Canadian company that specializes in the design and synthesis of novel small molecule ice recrystallization inhibitors (IRIs) that mitigate cellular damage to cells and tissues during cryopreservation," says co-founder Dr. Rob Ben, University of Ottawa. "These funds have facilitated the hiring of key personnel to fully commercialize the IRI technology and enter the global research and clinical markets."

###

About GlycoNet

GlycoNet is a pan-Canadian, multidisciplinary research network aiming to deliver solutions to important health issues and improve the quality of life of Canadians through the study of glycomics. GlycoNet is funded by the Networks of Centres of Excellence, a Government of Canada program that supports large-scale, academic-led research networks to build research capacity and accelerate the creation of new knowledge in a specific research area. For more information, visit http://www.glyconet.ca.

Media Contact

B. Poitras
[email protected]
780-492-4355
@glyconet_nce

Home

http://canadianglycomics.ca/glyconet-awards-grants-worth-90000-to-three-alberta-startup-companies/

Share12Tweet7Share2ShareShareShare1

Related Posts

Short Web-Based Dance Boosts Health in Older Adults

November 4, 2025

Evaluating Intermediate Care’s Effects on Healthcare Outcomes

November 4, 2025

Biodegradable Matrix Boosts Blood Vessel Growth for Stroke Recovery

November 4, 2025

Researchers Uncover Novel Method to Direct Stem Cell Fate

November 4, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1297 shares
    Share 518 Tweet 324
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    313 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    204 shares
    Share 82 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Reviving Resilience: The Role of Algae in Coral Recovery Post-Bleaching

Short Web-Based Dance Boosts Health in Older Adults

Evaluating Intermediate Care’s Effects on Healthcare Outcomes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.